Results 201 to 210 of about 23,450 (303)

GWAS of Second‐Generation Antihistamine Use: Locus Specificity and Highlighted Signalling Pathways

open access: yes
Clinical &Experimental Allergy, EarlyView.
M. Niemi   +15 more
wiley   +1 more source

Garadacimab for the long‐term prophylaxis of hereditary angioedema

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Hereditary angioedema (HAE), a rare and debilitating disease characterized by recurrent and spontaneous attacks of tissue swelling, has a high unmet therapeutic need, with many patients experiencing insufficient disease control with current prophylactic treatments.
Emel Aygören‐Pürsün   +5 more
wiley   +1 more source

The different face of skin‐rash induced by brentuximab vedotin

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background: Brentuximab vedotin (BV) is a targeted therapy for CD30‐expressing lymphomas, including Hodgkin lymphoma (HL) and cutaneous T‐cell lymphoma (CTCL). While peripheral neuropathy is the most common adverse event, BV‐induced skin rashes are less frequent and not well characterized.
Alessandro Pileri   +11 more
wiley   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach   +2 more
wiley   +1 more source

First-Generation Antihistamine Use in Geriatric Emergency Department Patients: Retrospective Review. [PDF]

open access: yesWest J Emerg Med
Killen E   +6 more
europepmc   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy